Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a stronger eylea dose cut eye injections in half?

NCT ID NCT07390253

Disease control Sponsor: Vienna Institute for Research in Ocular Surgery Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether switching wet AMD patients who don't respond well to the standard 2mg dose of aflibercept (Eylea) to a higher 8mg dose can extend the time between injections while keeping vision stable. Fifty adults who have already had at least four 2mg injections will receive the higher dose and be followed for 12 months. The goal is to see if fewer injections are needed without losing vision benefits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
aflibercept (8 mg injection)
What this could lead to
If successful, this could allow wet AMD patients to go longer between eye injections while keeping their vision stable.
What could go wrong
This is a small, early-phase study with only 50 participants. The higher dose may not work better or could cause more side effects like eye inflammation or vision changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2024

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with neovascular AMD, which are suboptimal responders to the current standard of care

Ages

21 to 105 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients, who received prior intravitreal anti-VEGF-treatment for nAMD with Aflibercept 2mg. A minimum of four injections of Aflibercept 2mg is required. Therefore 16-24 weeks prior treatment with anti-VEGF is required in line with an interval of 4-8 weeks. * Short treatment intervals of 4 or 8 weeks * nAMD * Age 21 or older * Written informed consent Exclusion Criteria: * Chronic treatment with Bevacizumab or Faricimab * Extensive macular fibrosis * Diabetic retinopathy * Other retinal pathologies (e.g. retinal vein occlusion) * Dense media opacities (cataract, corneal scars) * Vitreous hemorrhage * Ocular or periocular infections * Active intraocular inflammation * Hypersensitivity to the active substance or to any of the excipients * Prior Aflibercept 8mg treatment * Pregnancy (for women in reproductive age a pregnancy test will be performed)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neovascular (WET) age-related macular degeneration are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neovascular (WET) age-related macular degeneration

Contacts and locations

Locations

  • Vienna Institute for Research in Ocular Surgery

    Vienna, 1140, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.